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Abstract
Objective. ANCA-associated vasculitis (AAV) is characterized by a chronic relapsing course. Rituximab
(RTX) is an effective maintenance treatment; however, the long-term outcomes after its discontinuation are
unclear. The aim of this study was to explore the long-term outcomes of AAV patients treated with repeat-
dose RTX maintenance therapy.
Methods. AAV patients receiving a RTX treatment protocol consisting of an induction and maintenance
phase were included. For initial remission induction, RTX was dosed at 1 g every 2 weeks or 375 mg/m2
weekly for 4 consecutive weeks and for remission maintenance at 1 g every 6 months for 24 months. At
the first RTX administration, ongoing immunosuppressives were withdrawn.
Results. Sixty-nine patients were identified, 67 of whom were failing other therapies. Nine relapsed during
the RTX treatment protocol; however, all 69 were in remission at the end of the maintenance phase on a
median prednisolone dose of 2.5 mg/day and 9% were receiving additional immunosuppression. During
subsequent observation, 28 patients relapsed a median of 34.4 months after the last RTX infusion. Risk
factors for relapse were PR3-associated disease (P= 0.039), B cell return within 12 months of the last RTX
infusion (P= 0.0038) and switch from ANCA negativity to positivity (P= 0.0046). Two patients died and two
developed severe hypogammaglobulinaemia.
Conclusion. This study supports the efficacy and safety of a fixed-interval RTX maintenance regimen in
relapsing/refractory AAV. Relapses after discontinuation of maintenance therapy did occur, but at a lower
rate than after a single RTX induction course. PR3-associated disease, the switch from ANCA negative to
positive and the return of B cells within 12 months of the last RTX administration were risk factors for
further relapse.
Key words: anti-neutrophil cytoplasm antibody, granulomatosis with polyangiitis, microscopic polyangiitis, vas-
culitis, B cells, biologic therapies, maintenance treatment.
Rheumatology key messages
. Fixed-interval rituximab maintenance therapy appears effective in ANCA-associated vasculitis.
. After rituximab maintenance treatment, relapses are less frequent than after a single rituximab course in ANCA-
associated vasculitis.
. B cell return within 12 months and ANCA reversal from negative to positive may predict relapse in ANCA-
associated vasculitis patients.
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Introduction
ANCA-associated vasculitides (AAVs), including granulo-
matosis with polyangiitis and microscopic polyangiitis, are
small vessel vasculitides characterized by vasculitic and
granulomatous manifestations [1]. ANCA positivity is re-
ported in 90% of cases [2] and their specificity may be
directed against neutrophil PR3 or MPO. Classification
has been historically performed according to the clinical
phenotype together with ANCA positivity (but not specifi-
city) or histological confirmation [3], although a recent
GWAS study has challenged this convention by demon-
strating that, from a genetic perspective, AAV is made up
of two subgroups best defined by ANCA specificity rather
than clinical features [4]. Disease severity ranges from life-
or organ-threatening manifestations to milder forms. AAV
is characterized, particularly in the PR3-associated group
[5], by a chronic relapsing course leading to repeat expos-
ure to augmented immunosuppression culminating in ad-
verse events and damage [6].
Rituximab (RTX), an anti-CD20 monoclonal antibody, is
an effective induction treatment in AAV in both newly diag-
nosed and relapsing patients [7, 8]. The efficacy of repeat
dose RTX as maintenance therapy has been demon-
strated both retrospectively in relapsing and refractory pa-
tients [9, 10] and prospectively by the preliminary results
of a recent randomized trial comprising mainly patients
with newly diagnosed AAV [11]. However, a number of
factors remain unknown, including the ideal duration of
maintenance treatment [12], the effect of cumulative
RTX dose and whether or not redosing should be at a
fixed time interval or driven by rising ANCA titre, B cell
count or symptoms. Moreover, the long-term outcome
after discontinuation of RTX-based fixed-term mainten-
ance treatment is not known. Here we present the long-
term follow-up of a retrospective cohort of AAV patients
after 2 years of treatment with fixed-interval repeat-dose
RTX maintenance therapy.
Patients and methods
In 2006, a 24-month fixed-interval RTX re-treatment regi-
men was implemented for patients with relapsing or
refractory AAV at the Vasculitis and Lupus Clinic,
Addenbrooke’s Hospital, Cambridge, UK. All patients
with a diagnosis of granulomatosis with polyangiitis or
microscopic polyangiitis who have completed a RTX
maintenance strategy since 2006 are analysed in this
cohort. If ANCA was negative at the time of diagnosis,
then histological confirmation of AAV was required. This
cohort includes 53 patients from a previous report [9].
Patients’ clinical and laboratory data were reviewed up
to October 2013. In accordance with current UK ethical
guidelines, ethical approval was not required because this
work includes only retrospective data and all treatment
decisions pre-date the collection of data.
Treatment protocol
The RTX treatment protocol included an induction and a
maintenance phase. RTX was given at a dose of 1 g twice,
2 weeks apart or 375 mg/m2 weekly for 4 consecutive
weeks as induction therapy and then 1 g every 6 months
as maintenance therapy for 24 months overall. For pa-
tients perceived to be at high risk of relapse or who had
had severe disease flares, the maintenance treatment
period was extended beyond 24 months; however, all
such patients eventually discontinued RTX maintenance
therapy and have been included in this cohort. Patients
who had not completed the 24 month RTX treatment
protocol (due to insufficient follow-up at the time of data
analysis) were not included. Body surface area was cal-
culated using the Mosteller formula [13]. At each RTX ad-
ministration, all patients received premedication with i.v.
hydrocortisone 100 mg, i.v. chlorpheniramine 10 mg and
oral paracetamol 1 g before the infusion. Prophylactic tri-
methoprimsulphamethoxazole was not routinely admin-
istered. At the time of first RTX dose, any pre-existing
maintenance immunosuppressive agents were routinely
withdrawn and the prednisolone dose was increased ac-
cording to flare severity; other immunosuppressive treat-
ments (e.g. i.v. CYC or plasma exchange) were
considered only for life- or organ-threatening flares. The
prednisolone dose was tapered during follow-up, aiming
for complete withdrawal or <5 mg/day. Other immuno-
suppressive agents were not routinely introduced follow-
ing completion of the RTX treatment protocol and patients
were monitored during regular clinical assessment.
Assessments
Disease activity was assessed using the Disease Extent
Index (DEI) score [14], the physician assessment of dis-
ease activity and the prednisolone dose. Recurrent dis-
ease (relapse) at the time of the first RTX infusion was
defined as a DEI score 52 and physician assessment of
active disease requiring a therapeutic intervention in add-
ition to an increase in steroid dose. Refractory disease
was defined as a DEI score 52 despite a full course of
first-line immunosuppressive and CS treatment. Patients
who received RTX for consolidation of remission included
those with grumbling disease (low-grade disease activity
based on clinical assessment) that did not fulfil the criteria
for recurrent or refractory disease, patients unable to
taper prednisolone to <15 mg/day and patients for
whom steroid-free regimens were strongly advised (e.g.
co-existent diabetes, severe osteoporosis or chronic in-
fection). Disease response was assessed every 34
months during and after the RTX treatment protocol.
In terms of response to RTX treatment, we defined full
remission as a DEI score 42 with prednisolone dose
410 mg and physician assessment of full remission and
partial remission as a reduction of the DEI score >50%
with physician judgement of partial remission. Relapses
were classified as major or minor. Major relapses were
those with life- or organ-threatening manifestations that
would have historically been managed with CYC; minor
relapses were those episodes of disease activity requiring
an increase in therapy such as early RTX administration,
addition of another immunosuppressive agent, i.v. methyl-
prednisolone or oral prednisolone >20 mg/day.
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Severe adverse events (SAEs) were defined as epi-
sodes requiring hospitalization, i.v. antibiotic therapy,
malignancies or death. Patient follow-up was not cen-
sored at the time of the relapse in order to record subse-
quent SAEs. ANCA positivity required a positive ELISA for
PR3 or MPO and B cell depletion with a CD19+ cell count
<0.01 109/l. Hypogammaglobulinaemia was defined by
an IgG level <6 g/l for at least 3 consecutive months and
subclassified as either moderate (35.9 g/l) or severe
(<3 g/l).
Statistics
Statistical analysis was performed using SPSS version
20.0 (IBM, Armonk, NY, USA) and GraphPad version 5
(GraphPad Software, La Jolla, CA, USA). Results are ex-
pressed as value and percentage for categorical variables
and median and interquartile range (IQR) for continuous
variables. Changes in variables including DEI, IgG level
and prednisolone dose were compared by a related-
sample Wilcoxon matched pairs test, paired t-test or
Friedman test when appropriate. Proportions of patients
were compared using a chi-squared, Fisher test or logistic
regression. Time to relapse was assessed by
KaplanMeier survival analysis, and if comparisons be-
tween populations were required, the log-rank test was
used. P-values< 0.05 were considered significant.
Results
Patient characteristics
Sixty-nine patients were followed up for a median of 59.3
months (IQR 44.573.3), including a median of 19.9
months of post-relapse follow-up in the relapsing group.
The total follow-up was 334.7 patient-years. The baseline
characteristics of our cohort are reported in Table 1.
Median DEI at the time of first RTX administration was
2.5; 47 of 69 patients (68%) had active disease while 20
of 69 (29%) received RTX for consolidation of disease re-
mission. In the latter group, 16 patients were treated with
RTX for low-grade disease activity (due mainly to persist-
ent ENT symptoms); 3 due to an inability to taper the
prednisolone dose to <15 mg/day and 1 because of a
pulmonary aspergilloma, thus a steroid-free regimen was
felt to be safer. In addition, in the subgroup with persistent
low-grade disease activity, 5 of 16 patients required a
steroid-free maintenance regimen due to significant ster-
oid-related side effects. Two patients (3%) with a new
diagnosis who received RTX induction followed by a
repeat-dose maintenance course as a first-line thera-
peutic approach were also included. Sites showing
active disease were ENT in 35 patients (57%), lung in 20
(29%), joints in 16 (23%), systemic symptoms in 15 (22%),
kidney in 8 (12%), eye in 8 (12%), skin and peripheral
nervous system in 5 patients each (7%) and CNS in 4
patients (6%).
Treatment
The median oral prednisolone dose at the first RTX admin-
istration was 10 mg/day (IQR 515). At study entry, 14 of
69 patients (20%) received other treatments in order to
achieve rapid disease control: 8 i.v. methylprednisolone,
6 i.v. CYC, 2 plasma exchange, 1 AZA and 1 MMF.
Median RTX treatment protocol length was 24.1 months
(IQR 2125.6), during which a median of five RTX cycles
were administered corresponding to a median dose of 6 g
(IQR 66.5). Seven patients had an overall treatment
length >30 months with three treated for >40 months.
The median overall dose of RTX per square metre of
body surface area was 3154.9 mg (IQR 2743.43658.5).
RTX maintenance treatment outcome
During the RTX maintenance treatment period, nine pa-
tients (13%) relapsed a median of 11 months after the first
RTX infusion, including two major relapses. These epi-
sodes required an increased steroid dose in three, an
early unplanned RTX infusion in one and five required
the addition of another immunosuppressive agent (MTX
in two, IVIG in one, AZA in one and LEF in one). In these
TABLE 1 Demographic characteristics at the beginning of
RTX maintenance treatment
Age, median (IQR), years 52.02 (40.1262.87)
Sex, male 28/69 (41)
Diagnosis
GPA 62/69 (90)
MPA 7/69 (10)
Prior disease duration,
median (IQR), months
60.2 (20.7120)
Prior CYC 63/69 (91)
Cumulative dose,
median (IQR), g
13.45 (8.2530)
Prior therapies
MMF 53/69 (77)
AZA 48/69 (70)
MTX 24/69 (35)
RTX 15/69 (22)
Othera 15/69 (22)
IVIG 15/69 (22)
Anti-TNF-a 10/69 (15)
Plasma exchange 8/69 (12)
Alemtuzumab 6/69 (9)
Number of previous
immunosuppressives
3 (24)
Historical ANCA status
PR3 51/69 (74)
MPO 10/69 (15)
Indication
Active disease 47/69 (68)
Consolidation of remission 20/69 (29)
New diagnosis 2/69 (3)
DEI at entry 2.5 (24)
ANCA at entry
PR3 38/69 (55)
MPO 8/69 (12)
Results are expressed as n/N (%) unless indicated otherwise.
DEI: disease extent index; GPA: granulomatosis with polyan-
giitis; IQR: interquartile range; MPA: microscopic polyangiitis;
RTX: rituximab. aOther treatment: deoxyspergualin, LEF, anti-
CD18, abatacept, HCQ, tacrolimus.
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patients, the sites with active disease were the ENT in five,
lung and joints in two, CNS in one and peripheral nervous
system in one; systemic symptoms were reported by two
patients. Despite these disease flares, all 9 patients con-
tinued the predetermined RTX treatment protocol and
upon completion all 69 patients were in remission; 33
(48%) were not receiving glucocorticoids and 63 of 69
(91%) were not receiving other immunosuppressants.
Two patients were receiving replacement IVIG for moder-
ate hypogammaglobulinaemia and recurrent infections,
one IVIG treatment for peripheral neuropathy, two im-
munosuppression following renal transplantation and
one AZA started for relapse during the RTX maintenance
treatment period. The median prednisolone dose was
2.5 mg/day (IQR 05), which was lower compared with
the onset of RTX treatment (P< 0.0001) (Fig. 1). Fifteen
patients (22%) were ANCA positive at the end of the
RTX maintenance treatment compared with 46 of 69
(67%) at the beginning (P< 0.0001). The median IgG
levels remained within normal range, although they
decreased from 9.3 g/l (IQR 7.210.4) before RTX to 8 g/l
(IQR 69.2) at the end of the treatment course (P< 0.0001)
(Fig. 2).
Follow-up post-RTX maintenance treatment
Following the completion of the 24 month RTX treatment
protocol, all 69 patients were in remission and were there-
fore included in the post-treatment survey with a median
post-treatment follow-up time of 34.5 months (IQR
19.247.2). Post-treatment follow-up of at least 6
months was available in 65 of 69 patients 94%).
The median post-treatment relapse-free survival of our
cohort was 34.4 months (Fig. 3). Twenty-eight patients
experienced relapse after a median time of 15.5 months
(IQR 1222.9); 12 (43%) of these disease flares were clas-
sified as major. Within 1 year of post-treatment follow-up,
11% of the patients relapsed, 36% within 2 years, 51%
within 3 years, 55% within 4 years and 55% within 5 years.
Among the relapsing patients, 12 were re-treated with
RTX monotherapy, 10 with RTX and corticosteroids and
the remaining 6 patients received steroids alone, alemtu-
zumab, AZA, MMF or CYC. Six months after treatment for
relapse, 19 of 28 patients (68%) were in complete remis-
sion, 6 (21%) in partial remission and 3 (11%) were show-
ing active disease.
The median follow-up of the 41 non-relapsing patients
was 27.3 months (IQR 17.145.4). At their last assess-
ment, the median prednisolone dose was 0 mg/day (IQR
05), lower than at the end of the RTX treatment protocol
(P= 0.046). Of these patients, 14 (34%) were ANCA posi-
tive and 28 (68%) had experienced B cell return.
Factors predictive of relapse
At the time of relapse, 14 of 28 (50%) were ANCA positive
and 20 of 28 (71%) had experienced B cell return.
FIG. 1 Glucocorticoid treatment during follow-up
Data include all 69 AAV patients who received RTX
induction and maintenance treatment. Shown are the
proportion of patients either receiving (grey bars) or not
receiving (white bars) glucocorticoids before rituximab
(RTX) maintenance treatment, immediately after RTX
maintenance treatment and at the last follow-up (median
34.5 months since last RTX administration). The P-values
reported above the histograms refer to comparison of the
different proportion of patients at the different timelines
(Fisher’s exact test). Median prednisolone dose is
represented with dots (median) and whiskers (25th75th
percentiles). Patient follow-up was censored at the time of
the relapse considering the steroid dose at the assess-
ment immediately before the relapse. *P< 0.0001
compared with the beginning of the RTX treatment
protocol (Wilcoxon matched pairs test). AAV: ANCA-
associated vasculitis; RTX: rituximab.
FIG. 2 Change in IgG level during follow-up
Data include all 69 AAV patients who received rituximab
induction and maintenance treatment (paired t-test). The
lines inside the boxes represent the median level, the
edge of the boxes the 25th75th percentiles, the whiskers
the 5th95th percentiles and the dots the outliers. The
grey area represents the reference range. AAV: ANCA-
associated vasculitis.
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However, compared with the subgroup of non-relapsing
patients, neither factor differed significantly (P= 0.4984
and P= 1.000, respectively). None of the patients’ charac-
teristics at the start of the RTX treatment protocol (disease
duration, age, CYC cumulative dose, number of previous
immunosuppressives, DEI score, sites showing active dis-
ease or the presence of granulomatous disease) were
associated with the risk of relapse during post-treatment
follow-up. Among baseline characteristics (age, sex, DEI
score, sites showing active disease and antibody specifi-
city), only PR3 ANCA positivity was associated with risk of
relapse after RTX maintenance treatment (P= 0.039).
During post-treatment follow-up, among the 54 patients
who were ANCA negative at the end of the RTX mainten-
ance treatment period, 13 of 54 (24%) switched from
ANCA negative to positive and 10 of 13 (77%) relapsed
a median of 1.8 months following the ANCA switch, there-
fore ANCA switch from negative to positive was asso-
ciated with an increased risk of relapse [odds ratio (OR)
7.04, P= 0.0046]. After stratification of the relapses ac-
cording to severity, the ANCA switch was associated
with the risk of major relapse (P= 0.039) but not minor
(P= 0.1655). When the data were consistently available,
patients whose B cells were detectable within 12
months of the last RTX maintenance infusion had a shorter
time to relapse than those whose B cells returned after 12
months (P= 0.0052) (Fig. 4). Interestingly, two patients
included in the analysis experienced B cell return shortly
after relapse (4 months in both cases), with the difference
between the two groups remaining significant also after
their exclusion (P= 0.00931).
Severe adverse events
Ninety-three severe adverse events in 36 patients were
recorded during the treatment and post-treatment
follow-up period. Severe infections were documented in
20 (29%) patients, 57% affecting the lower respiratory
tract. Fourteen (20%) patients were hospitalized for
reasons other than infection, most commonly ortho-
paedic: hip replacements in two cases and bone fracture
in one. Malignancies (lung, bladder, peritoneal and breast)
were recorded in four patients. Two patients developed
self-limiting late-onset neutropenia: one required hospital
admission for a fever and pre-emptive antibiotic treat-
ment, but neither received granulocyte-stimulating
agents. Two patients died: one as a result of peritoneal
carcinoma and one of unknown cause 55 months after the
last RTX infusion.
Twenty-eight (41%) patients developed IgG hypogam-
maglobulinaemia at some point during follow-up, with
severe hypogammaglobulinaemia recorded in two (7%).
Two patients with moderate hypogammaglobulinaemia
required IVIG replacement for recurrent infections.
Discussion
AAV is characterized by a chronic relapsing course.
Relapse leads to increased immunosuppressive exposure
and consequent toxicity. Two randomized controlled trials
have shown RTX to be an effective induction treatment in
patients with both newly diagnosed and relapsing disease
[7, 8]. However, the effect of a single course of RTX is not
sustained, with 50% of the patients relapsing within 1
year, with a higher risk associated with PR3 ANCA posi-
tivity [9, 15].
Preliminary results suggest that repeat-dose RTX is ef-
fective as a maintenance therapy in AAV [911]. However,
the optimal treatment duration and RTX dose remain un-
clear [12] and it is still debated whether to re-treat at a
fixed time interval or on the basis of B cell count, ANCA
titre or disease symptoms. Moreover, the identification of
prognostic factors able to identify patients more likely to
relapse on cessation of RTX treatment is still an area of
unmet need.
In this retrospective study, we found that fixed-interval
repeat-dose RTX was an effective maintenance strategy,
both in terms of disease control, with only 13% of patients
experiencing a relapse during the treatment period, and
also in enabling steroid taper or withdrawal. Current evi-
dence suggests that maintenance treatment in AAV
should be continued for 1824 months [1618].
FIG. 3 Relapse-free survival after rituximab (RTX) main-
tenance treatment withdrawal
The dashed line represents the outcome during the RTX
maintenance treatment. Although nine patients experi-
enced relapse during this therapeutic course, all of them
completed the RTX maintenance treatment and were in
remission at the end of it and therefore were included in
the subsequent analysis.
FIG. 4 Relapse-free survival stratified by B cell return
within or after 12 months of the last rituximab dose
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However, despite successful remission induction, the risk
of relapse is high (35%) with standard maintenance treat-
ment with first-line agents (AZA/MTX), especially after
cessation of immunosuppressive medication [19]. In
2006 we implemented a 2 year repeat-dose RTX mainten-
ance regimen trying to find equipoise between the guide-
lines for duration of maintenance therapy and the debated
long-term safety profile of repeat RTX dosing. Following
cessation of this 2 year fixed-interval RTX maintenance
treatment, we observed further relapses in 28 of 69 pa-
tients, with a median post-treatment relapse-free survival
of 34.4 months. This median relapse-free survival was
longer than that observed in our own refractory/relapsing
patients historically treated with a single RTX course
(12 months) (Fig. 5) [9].
In our population, relapses started to occur as early as 6
months after the last RTX infusion, but were more
common between months 10 and 24. The majority of
the relapsing patients were successfully re-treated with
further RTX. These data suggest that RTX maintenance
treatment may induce long-lasting remission of >24
months in 50% of patients, while for the remainder it
may only be able to keep the disease inactive while on-
going dosing is employed. However, despite the long fol-
low-up of our population, the number of patients at risk
after the last recorded event at month 44 was small (12 pa-
tients), suggesting caution in the interpretation of these
results.
The identification of factors predictive of relapse is
necessary to pre-emptively identify the group likely to re-
lapse after maintenance treatment. Several biomarkers
and single nucleotide polymorphisms have been pro-
posed, as well as the B cell phenotype, as potential prog-
nostic factors in patients receiving RTX [2022]: a memory
CD27+ B cell phenotype picture has been associated with
relapse in SLE, while a decrease in regulatory CD5+ B
cells has been associated with relapses in AAV [23, 24].
However, for all of these potential biomarkers, validation is
still required, and their use at the moment is limited to the
field of research, with their application to clinical practice
still somewhat distant.
We confirm in our cohort the higher risk of relapse in the
PR3 ANCA-associated group. Notably, 78% of the pa-
tients were ANCA negative by the end of RTX mainten-
ance. During the follow-up phase, a switch from ANCA
negativity to positivity conferred a 7-fold increased risk
of relapse, with a very short median time to flare (1.8
months), suggesting that very close follow-up is required
to pre-emptively identify patients at risk of relapse on this
basis. ANCA recurrence was associated with the risk of
major relapse. In 90% of these patients, B cells had re-
turned prior to ANCA recurrence, suggesting a conse-
quential relationship between these events, with B cells
producing ANCA as one of their many functions [25]. In
addition, patients experiencing B cell return within 12
months of the last RTX dose relapsed significantly earlier
than those whose B cells returned after 12 months.
Depletion of tissue resident B cells may not necessarily
be as effective as circulating B cells [26], and early re-
population might represent incomplete B cell depletion
in tissues despite repeat dosing of RTX [27].
At the time of this study, safety concerns remained re-
garding the development of acquired immunodeficiency
following long courses of repeated RTX treatment and
therefore we decided to consider extending treatment
beyond 2 years only in patients perceived to be at very
high risk of relapse or in patients who had experienced
life- or major organ-threatening manifestations previously.
Reassuringly, in the reported cohort, the rate of severe
adverse events was relatively low and in keeping
with other relapsing/refractory AAV cohorts treated
with different therapeutic approaches in our centre
[2830]. We should take into account that the
relapsing and refractory nature of disease in this popula-
tion, the prior high immunosuppressive burden and the
very long follow-up may have influenced our SAE rate.
Hypogammaglobulinaemia was common, occurring in
41% of patients at some point during follow-up, but was
severe in only two patients. In addition, IVIG replacement
was required in the context of recurrent infections in two
patients with moderately low IgG levels, suggesting that
IgG hypogammaglobulinaemia is only one component
among the possible risk factors for recurrent infection in
this group of patients. During the therapeutic course, the
IgG levels decreased significantly, although the median
value in the overall population remained within the
normal range. Once RTX treatment was complete, IgG
levels stabilized.
In conclusion, our results suggest that a fixed-interval
RTX maintenance regimen in relapsing/refractory AAV ef-
fectively prevents relapse. Withdrawal of RTX after 2 years
is possible, with 50% of patients remaining in long-lasting
remission and 50% relapsing over 3 years; the relapse
rate was significantly lower than that after a single RTX
course. The relapse risk was higher in patients with B cell
return within 12 months of the last RTX infusion, return of
ANCA positivity and PR3-associated disease. In order to
allow early identification of major relapses in patients not
FIG. 5 Relapse-free survival in two cohorts of relapsing
ANCA-associated vasculitis patients
The green line represents patients treated with rituximab
(RTX) induction and maintenance treatment and the red
line patients treated only with RTX induction (log-rank test).
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on immunosuppression, we recommend monitoring B
cells and ANCA after RTX withdrawal. Better biomarkers
are required to identify patients at relapse risk after RTX
maintenance therapy withdrawal.
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A case of relapsing neurosarcoidosis with brain
nodules and hydrocephalus successfully treated
by corticosteroid and methotrexate
SIR, A 45-year-old woman presented with a 2-month his-
tory of progressive cognitive dysfunction and red plaques
on her extremities (Fig. 1A). She was diagnosed as having
neurosarcoidosis (NS) by brain biopsy (Fig. 1B) 12 years
before presenting and had been prescribed prednisolone
5 mg/day for the past 6 years. Laboratory examinations
showed an increased serum angiotensin-converting
enzyme level of 29.3 IU/l. Neither infection nor malig-
nancy was detected. Skin biopsy of plaques revealed
non-caseating epithelioid cell granuloma with giant cells
(Fig. 1C, arrows), like the previous brain pathology.
Contrast-enhanced MRI of the brain showed numerous
high-intensity foci on the brain surface and hydrocephalus
(Fig. 1D, arrows). Queckenstedt’s sign was positive.
She was diagnosed as a relapse of NS. She underwent
methylprednisolone pulse therapy, followed by prednisol-
one 50 mg/day and MTX 12 mg/week. After 4 weeks from
the initiation of therapy, the high-intensity foci dis-
appeared (Fig. 1E), Queckenstedt’s sign was negative
and her cognitive function recovered.
NS develops in 513% of sarcoidosis patients [1].
Diagnosis of NS is challenging because of the variety of
its clinical presentation and the difficulty of histological
confirmation. Although hydrocephalus is a rare manifest-
ation (57% of NS patients), it has a poor long-term prog-
nosis [2]. In our case, multiple brain nodules and cognitive
dysfunction improved remarkably, while hydrocephalus
was unchanged after treatment.
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FIG. 1 Neurosarcoidosis with brain nodules and hydroceph-
alus accompanied with skin plaques successfully treated by
immunosuppressive therapy
(A) Red plaques on the extremities on admission. (B) Brain
biopsy showing non-caseating epithelioid cell granulomas.
(C) Skin biopsy of plaques showing non-caseating epithelioid
cell granuloma with giant cells (indicated by arrows). (D)
Contrast-enhanced MRI of the brain before treatment show-
ing multiple high-intensity foci (indicated by arrows) and
hydrocephalus. (E) Contrast-enhanced MRI of the brain 4
weeks after initiation of treatment showing disappearance of
the high-intensity foci.
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